Shlyakhtychenko T. Peculiarities of cytokine profile in the prediction of the course and effectiveness of tyrosinekinase inhibitors therapy among patients with chronic myeloid leukemia

Object: Peripheral blood and bone marrow of patients with chronic phase of CML in the dynamics of therapy with imatinib.Аim:Improvement of prognostic criteria for chronic myeloid leukemia and response to targeting therapy with imatinib in patients with CML.The features of secretion and imbalance of levels of inflammatory and anti-inflammatory cytokines in patients with chronic phase of CML in the dynamics of a targeted therapy with Imatinib, depending on the cytogenetic reduction of the Ph + tumor cell clone, were determined for the first time. It has been established that the violation of hematopoiesis with CML is accompanied by a reliable increase in the levels of as pro-inflammatory cytokines (IL-1beta, IL-6, IL-8, TNF-alpha), as well as anti-inflammatory cytokines (IL-4, IL-10) against the background of significantly reduced levels of IL -2 and IFN-gamma in the bone marrow and peripheral blood.Medicine.